Sana Biotechnology

Develops engineered cell therapies for diseases

Seattle, Washington, United States

About Sana Biotechnology

Sana Biotechnology develops engineered cells aimed at treating and potentially curing various diseases. Their approach focuses on addressing the root causes of diseases by repairing genes within cells or replacing damaged cells. This method allows for the creation of new types of medicines that can improve patient outcomes significantly. Sana's main clients include healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The company invests heavily in research and development to discover and create new treatments, which they monetize through licensing agreements, partnerships, and direct sales. Unlike many competitors, Sana's focus on cellular and genetic medicine positions them uniquely in the biotechnology sector. Their goal is to lead in the development of therapies that target diseases at their genetic and cellular roots, ultimately enhancing patient care.

Seattle, WashingtonHeadquarters
2018Year Founded
$798.6MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Health Insurance
Paid Vacation
Paid Sick Leave
Paid Holidays
Disability Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Tuition Reimbursement
Student Loan Assistance
Employee Stock Purchase Plan
Commuter Benefits

Risks

Competition from companies like BlueRock Therapeutics may impact market share.
Resignation of key R&D figure, Dr. Douglas Williams, could disrupt innovation pipeline.
Reliance on PIPE offerings suggests potential financial instability or capital needs.

Differentiation

Sana focuses on engineered cells to treat diseases at genetic and cellular levels.
The company targets unmet needs in autoimmune diseases with innovative hypoimmune therapies.
Sana's strategic partnerships and licensing deals enhance its market presence and revenue potential.

Upsides

Fast Track designation for SC291 highlights potential in autoimmune disease treatment.
New Bothell facility boosts production capabilities for engineered cell therapies.
$189.75M PIPE offering indicates strong investor confidence and capital for R&D.

Funding

Total raised$798.61 M
Latest valuation$4.11 B
StageIPO